Welcome to our dedicated page for Dentsply Sirona news (Ticker: XRAY), a resource for investors and traders seeking the latest updates and insights on Dentsply Sirona stock.
DENTSPLY SIRONA Inc. develops, manufactures and markets professional dental products, dental technologies, oral health products and other consumable medical devices under a broad brand portfolio. News for XRAY commonly covers quarterly results, outlook updates, restructuring actions, capital allocation, debt reduction, share repurchases and changes to distribution relationships for dental equipment and connected technology solutions.
Company updates also focus on digital dentistry and imaging products, including CEREC systems, intraoral scanning, CBCT imaging, DS Core, Smart View - Detect and dental-dedicated MRI work with Siemens Healthineers. Additional product news includes Surity urinary incontinence devices from Wellspect HealthCare, along with regulatory clearances, CE markings, commercial launches, board changes and investor conference participation.
Dentsply Sirona (Nasdaq: XRAY) reported Q4 2025 net sales of $961M (+6.2% vs. Q4 2024; constant currency +2.5%) and Q4 adjusted EPS of $0.27. GAAP results included $144M goodwill and intangible impairments, producing a Q4 net loss of ($146M) and diluted loss per share of ($0.74).
Full‑year 2025 net sales were $3.68B (down 3.0%); FY adjusted EPS was $1.60. The company announced a restructuring with ~$55–65M charges, ~$120M annualized savings, elimination of the quarterly dividend, and FY 2026 guidance of $3.5B–$3.6B sales and adjusted EPS $1.40–$1.50.
Dentsply Sirona (Nasdaq: XRAY) announced the appointments of James D. Forbes and Brian P. McKeon to its Board of Directors, effective February 27, 2026. Forbes brings 30 years of healthcare investment banking experience and will join the Compensation & Human Capital Committee. McKeon brings 25 years of CFO experience and will join the Audit and Finance Committee and Science and Technology Committee. The appointments aim to strengthen strategic, financial and governance capabilities to support the company’s Return-to-Growth action plan. In connection with board refreshment, Willie Deese intends to retire and will not stand for re-election after 15 years of service.
Dentsply Sirona (NASDAQ:XRAY) and Burkhart Dental Supply expanded their distribution partnership effective April 1, 2026, with Burkhart adding Dentsply Sirona’s full dental technology portfolio to its existing preventive and restorative offerings.
This includes CEREC systems, Primescan and Primescan 2 scanners, Axeos and Orthophos imaging, and aims to simplify purchasing and local support for dental practices.
Dentsply Sirona (Nasdaq: XRAY) will host a conference call and live webcast on Thursday, February 26, 2026 at 4:30 p.m. EST to review fourth quarter and full year 2025 financial results. A press release and a presentation with summary financial information will be posted on the company’s Investors website prior to the call.
The live webcast and a replay will be available at https://investor.dentsplysirona.com, and registered participants may join the call via the provided registration link.
Wellspect HealthCare (XRAY) announced the U.S. launch of the Surity™ Female External Catheter, a non-invasive product intended to help women with severe urinary incontinence and their caregivers. The device is designed to prevent leakage, protect skin, and support extended overnight use while integrating with compatible urine collection systems.
The company said Surity™ addresses a gap in continence care for aging, neurologic, and mobility-limited populations. The female catheter is available for home purchase at www.surity.care, and a Surity™ urinary management system plus a male external catheter are planned for launch later in the year.
Dentsply Sirona (Nasdaq: XRAY) and Patterson Dental announced on January 14, 2026 the renewal of their U.S. dental technology distribution agreement. The partnership continues long‑standing distribution of Dentsply Sirona’s technology portfolio—including CEREC, Primescan, Axeos and Orthophos—to Patterson Dental customers, supported by service and support. The companies say the renewal aims to accelerate adoption of integrated, connected dentistry solutions that link devices, software and services to improve practice efficiency and patient care.
The agreement emphasizes continued access to Dentsply Sirona products through Patterson Dental and a joint focus on growth and innovation in dental technology distribution in the U.S.
Dentsply Sirona (Nasdaq: XRAY) and Benco Dental announced an expanded partnership on Jan 13, 2026 where Benco will begin offering Dentsply Sirona’s full dental technology portfolio to US customers, in addition to consumables.
Available products include CEREC systems and blocks, intraoral scanners Primescan/Primescan 2, and extraoral imaging Axeos and Orthophos. Benco will open dedicated Dentsply Sirona experiences in three CenterPoint showrooms near Los Angeles, Dallas, and the NYC–Philadelphia area to support digital adoption and hands-on demos.
Dentsply Sirona (Nasdaq: XRAY) appointed Donald Zurbay to its Board of Directors, effective January 10, 2026. Mr. Zurbay will join the Board’s Audit and Finance Committee and brings leadership experience as former CEO and CFO of Patterson Companies and prior CFO of St. Jude Medical. The Board increased from 10 to 11 members.
The Board also formed a four-member Growth and Value Creation Committee, co-chaired by Gregory Lucier and Daniel Scavilla, to oversee the company’s Return-to-Growth action plan referenced on November 7, 2025.
Dentsply Sirona (Nasdaq: XRAY) appointed Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28, 2026. The hire is intended to strengthen commercial execution, deepen customer relationships and accelerate growth across the Americas. Bezjak joins from Zimmer Biomet, brings more than 20 years of commercial leadership and experience leading multi‑billion‑dollar organizations, and has a track record of commercial transformations and revenue and operating income growth. Management highlights his experience in orthopedics and customer‑first field execution as aligned with the company’s goal to elevate service to the dental community.
Dentsply Sirona (Nasdaq: XRAY) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 3:00 p.m. PT (6:00 p.m. ET).
Dan Scavilla, President and CEO, will discuss the company's Connected Dentistry portfolio, dental market trends, and progress on its return-to-growth strategy. A live audio webcast and replay will be available via the company's Investors website at https://investor.dentsplysirona.com.